These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 32313074)

  • 21. Treating Specific Variants Causing Cystic Fibrosis.
    Cutting GR
    JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
    [No Abstract]   [Full Text] [Related]  

  • 22. Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators.
    Han ST; Rab A; Pellicore MJ; Davis EF; McCague AF; Evans TA; Joynt AT; Lu Z; Cai Z; Raraigh KS; Hong JS; Sheppard DN; Sorscher EJ; Cutting GR
    JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic β2AR stimulation limits CFTR activation in human airway epithelia.
    Brewington JJ; Backstrom J; Feldman A; Kramer EL; Moncivaiz JD; Ostmann AJ; Zhu X; Lu LJ; Clancy JP
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells.
    Ruffin M; Roussel L; Maillé É; Rousseau S; Brochiero E
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L635-L641. PubMed ID: 29351441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.
    Galietta LJ
    Paediatr Drugs; 2013 Oct; 15(5):393-402. PubMed ID: 23757197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New therapies for cystic fibrosis targeting the CFTR gene or the CFTR protein].
    Hubert D; Bui S; Marguet C; Colomb-Jung V; Murris-Espin M; Corvol H; Munck A
    Rev Mal Respir; 2016 Oct; 33(8):658-665. PubMed ID: 26806675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.
    Mitchell RM; Jones AM; Barry PJ
    Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tezacaftor for the treatment of cystic fibrosis.
    Sala MA; Jain M
    Expert Rev Respir Med; 2018 Sep; 12(9):725-732. PubMed ID: 30073878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy.
    Connett GJ
    Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M
    Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622
    [No Abstract]   [Full Text] [Related]  

  • 32. Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis.
    McCarthy C; Brewington JJ; Harkness B; Clancy JP; Trapnell BC
    Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29563174
    [No Abstract]   [Full Text] [Related]  

  • 33. Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies.
    Jennings MT; Flume PA
    Ann Am Thorac Soc; 2018 Aug; 15(8):897-902. PubMed ID: 29812963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.
    Elborn JS; Ramsey B; Wainwright C; Boyle M
    Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855
    [No Abstract]   [Full Text] [Related]  

  • 35. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
    Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
    Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Causal therapy is available].
    Meißner T
    MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324018
    [No Abstract]   [Full Text] [Related]  

  • 37. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis.
    Cheng PC; Alexiou S; Rubenstein RC
    Expert Rev Respir Med; 2019 May; 13(5):417-423. PubMed ID: 30929526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor.
    Mainz JG; Michl RK; Beiersdorf N; Lorenz M; Schneider U; Groten T; Jaudszus A
    Klin Padiatr; 2019 Sep; 231(5):271-273. PubMed ID: 31408905
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis.
    Harwood KH; McQuade RM; Jarnicki A; Schneider-Futschik EK
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.